SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-017549
Filing Date
2022-11-14
Accepted
2022-11-14 07:03:21
Documents
17
Period of Report
2022-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20221109x8k.htm   iXBRL 8-K 43275
2 EX-99.1 plx-20221109xex99d1.htm EX-99.1 197456
3 EX-99.2 plx-20221109xex99d2.htm EX-99.2 27397
4 GRAPHIC plx-20221109xex99d2001.jpg GRAPHIC 5450
5 GRAPHIC plx-20221109xex99d2002.jpg GRAPHIC 11216
6 GRAPHIC plx-20221109xex99d1001.jpg GRAPHIC 5450
  Complete submission text file 0001558370-22-017549.txt   444853

Data Files

Seq Description Document Type Size
7 EX-101.SCH plx-20221109.xsd EX-101.SCH 3265
8 EX-101.LAB plx-20221109_lab.xml EX-101.LAB 16110
9 EX-101.PRE plx-20221109_pre.xml EX-101.PRE 10855
11 EXTRACTED XBRL INSTANCE DOCUMENT plx-20221109x8k_htm.xml XML 4866
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 221380090
SIC: 2836 Biological Products, (No Diagnostic Substances)